about
Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problemPharmacological treatments for chronic hepatitis B liver disease: a network meta-analysisLevamisole for chronic hepatitis BHepatitis B virus polymerase suppresses NF-κB signaling by inhibiting the activity of IKKs via interaction with Hsp90βPre- and Post-Transplant Antiviral Therapy (HBV, HCV)Liver Failure due to Acute Viral Hepatitis (A-E)Links between Human LINE-1 Retrotransposons and Hepatitis Virus-Related Hepatocellular CarcinomaImmune Activation in the Liver by Nucleic AcidsMicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic ConsiderationsAlanine aminotransferase-old biomarker and new concept: a reviewThe Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis BSeroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis BHepatitis B Vaccination in Pregnancy in the United StatesPathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic backgroundHuman liver chimeric mice provide a model for hepatitis B and C virus infection and treatmentCurrent progress in the development of therapeutic vaccines for chronic hepatitis B virus infectionHepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinomaUse of Aptamers as Diagnostics Tools and Antiviral Agents for Human VirusesCirculating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinomaCurrent and future antiviral drug therapies of hepatitis B chronic infectionDynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencingSelective hepatitis B virus vaccination has reduced hepatitis B virus transmission in the NetherlandsAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsAbbott RealTime HBV assay is more sensitive in detection of low viral load and little impacted by drug resistant mutation in chronic hepatitis B patients under nucleot(s)ide analogues therapyGenomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practiceHepatitis B virus infection in Latin America: a genomic medicine approachProtective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China.Recent advances in micro/nanotechnologies for global control of hepatitis B infectionNon invasive tools for the diagnosis of liver cirrhosis.Unrecognized hepatitis B in pre-screened children with hematologic and oncologic conditions.Hepatitis B Virus Immunopathology, Model Systems, and Current TherapiesTo treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy.Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients.Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin.A novel system for predicting liver histopathology in patients with chronic hepatitis BOptimization therapy for the treatment of chronic hepatitis BEarly hepatitis B viral DNA clearance predicts treatment response at week 96Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa.Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG.Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment
P2860
Q21093293-27D06C63-B407-47F9-9FE4-06AA75C98D37Q24186878-892A7D8F-3519-45F0-9A11-8F9165E7A3AAQ24236771-18C0A58A-6B68-4339-9BC7-6A3B0DEAD342Q24338960-6A4DEA43-9B78-457B-ACDA-ACBC658DBFF6Q26740319-60ED5969-2870-4D35-815E-DF70651A5FB1Q26740326-100BD560-2DC6-4D0F-9DEC-AE7511D44B70Q26744497-DEB44740-8656-4310-B4F4-76AEA03B61B3Q26746467-E6423016-679F-405C-A3CD-0F608A62135EQ26773183-B7C94D50-E4CB-4618-9E03-E2B2F8772873Q26828819-C56E5C9E-0D55-4722-A0B5-BEA70546BCE4Q27007019-F16B14F1-0C2F-4D8D-8CA2-94CD7B627405Q27023737-73919804-D037-438E-B616-129FB6B7B21DQ27026187-DF3A6489-08F7-4BF5-9644-262F05AA7278Q27317287-75904049-7561-4FDF-832C-59F3954DB2A2Q27490974-8E38C7DF-C47B-49DF-A061-CD28C2E6C595Q28076279-9F3ABDE9-7023-43D4-940A-9E16A0EEE4C1Q28076535-47E8E610-B3E0-437B-B809-2F971D66955DQ28079654-1F22C64A-61B6-4C34-8A37-319D671D11A6Q28080175-121433D2-54DA-48DF-930B-911FEA1920A4Q28084820-6F7FE065-2A42-40B5-AFDB-1ADDBFEC4600Q28482355-6234405F-D796-4E1D-88AD-4DC1E5B2DF8EQ28534948-F031AEB8-9A3A-4AFD-BCB7-D34F2335E0E1Q28535003-9460FF1E-A139-434A-AB93-AD4D74AE3835Q28540452-37434687-B1F8-4A09-B233-69049ED12EC4Q28543022-64BD0FB1-9C61-496C-98D1-C73F080513C2Q28657861-C8094DF8-C8CB-44F6-9CB9-835EF183E91BQ30362020-A68D0991-7CBB-4A98-B55F-DB131316670FQ30394611-0B923486-8101-473A-B041-C7F73AF6073EQ30421450-3CECC34A-52F7-48A4-BA4E-61F8EAE7C95DQ33411579-0DD44D41-1175-4A47-AF59-A6D9EF5CEA91Q33559657-61D993C3-F28A-4530-9646-A77AFE15DCF6Q33563893-8A758F4D-2B46-4F31-AE49-45903EA41EC1Q33590508-F268CD80-4895-43CC-A334-CC09EE95D8F2Q33596807-28CEE352-4AE9-4157-B920-A5F4906F2892Q33621252-CB491578-4E9D-4366-A53D-49A7A71358A0Q33626813-FADA1749-6C8A-46A5-92A9-4F4CF414EBD3Q33628420-86AFC5FB-DC73-43B3-8AC4-E257C957601BQ33655929-F2958E4E-53C2-4F64-938E-734F173265A3Q33694522-0FB3C02C-35EA-438E-9202-CBF17B15FE4DQ33747793-83A8BFFC-12E9-4C80-B7BC-A3743B370776
P2860
description
im Oktober 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 October 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2008
@uk
name
Hepatitis B Virus Infection
@en
Hepatitis B Virus Infection
@nl
type
label
Hepatitis B Virus Infection
@en
Hepatitis B Virus Infection
@nl
prefLabel
Hepatitis B Virus Infection
@en
Hepatitis B Virus Infection
@nl
P356
P1476
Hepatitis B virus infection
@en
P2093
Jules L. Dienstag
P304
P356
10.1056/NEJMRA0801644
P407
P50
P577
2008-10-01T00:00:00Z